Aeglea BioTherapeutics' Series B Round

Aeglea BioTherapeutics raised a round of funding on March 23, 2015.

Aeglea was founded in 2013 to develop engineered human enzymes. Aeglea's pipeline of engineered human enzymes includes AEB1102, which is expected to enter into clinical trials in both hyperargininemia…

Articles about Aeglea BioTherapeutics' Series B Round: